This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
HCPLive
MAY 20, 2024
A numerically slower decline in eGFR was reported in the finerenone cohort after hospitalization for heart failure when compared with placebo.
116 
Cardiovascular Diabetology
MARCH 21, 2025
Mineralocorticoid receptor antagonists (MRAs) are often underutilized in patients with heart failure (HF), particularly those with diabetes and/or chronic kidney disease (CKD). However, the impact of concurren.
HCPLive
FEBRUARY 12, 2025
Meta-analysis suggests iron therapy lowers the risk of heart failure hospitalization and cardiovascular death in patients with chronic kidney disease.
120 
DAIC
MARCH 26, 2025
2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients (REDEFINE-HF). 4 Approximately 6.7 million adults in the U.S. NCT 06008197.
Cardiovascular Diabetology
JANUARY 8, 2024
Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes.
Med Page Today
APRIL 3, 2024
(MedPage Today) -- Using a personalized algorithm to identify primary care patients with chronic kidney disease (CKD), type 2 diabetes, and hypertension (the kidney-dysfunction triad) -- plus practice facilitators to help providers deliver guideline.
HCPLive
MARCH 25, 2024
Chronic kidney disease was linked to increased mortality, higher costs, and the need for mechanical ventilation among hospitalized patients with sickle cell disease.
Journal of the American Heart Association
DECEMBER 24, 2024
BackgroundThis realworld evidence study compared risks of cardiovascular events in hospital settings among patients with chronic kidney disease (CKD) with and without hyperkalemia.Methods and ResultsAdults with CKD stages 3b/4 with and without hyperkalemia were identified from Optum's deidentified Market Clarity Data (January 2016August 2022).
HeartRhythm
APRIL 30, 2024
Cardiac implantable electronic device (CIED) infections are a burden to hospitals and costly for health care systems. Chronic kidney disease (CKD) increases the risk of CIED infections. CKD may also have an impact on the severity of the infection and hospitalization.
European Journal of Heart Failure
JANUARY 17, 2025
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: a FIDELITY analysis. The incidence of hyperkalaemia leading to hospitalization or study drug discontinuation was low across treatment groups irrespective of diuretic use. Out of 12990 patients, 51.6%
European Journal of Heart Failure
FEBRUARY 5, 2025
Meta-analysis on the main outcomes of angiotensin receptorneprilysin inhibitor (ARNI) in heart failure (HF) patients with end-stage kidney disease (ESKD) on dialysis. However, the evidence on the benefits of ARNI in HF patients with end-stage kidney disease (ESKD) undergoing dialysis is limited.
DAIC
APRIL 6, 2024
However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. To have a 25% to 30% reduction in heart failure hospitalizations is pretty clinically meaningful, but if you put it together with all-cause mortality, it was not a positive study for our primary endpoint.”
European Journal of Heart Failure
OCTOBER 18, 2023
Mineralocorticoid receptor antagonist (MRA) use in severe chronic kidney disease and heart failure with reduced ejection fraction (HFrEF). composite of dialysis/renal death/hospitalization for renal failure or hyperkalaemia) (hazard ratio [HR] 1.04, 95% confidence interval [CI] 0.98–1.10),
DAIC
APRIL 30, 2024
Getty Images milla1cf Tue, 04/30/2024 - 12:56 April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center ( VUMC ) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure , a leading cause of hospitalization and death. hospitals from emergency rooms.
105 
DAIC
JULY 30, 2024
Although the application of ICDs in patients with CHF is backed by substantial evidence, these studies did not include people with chronic kidney disease (CKD), who are an important clinical population. The study ultimately included 1,676 patients who had visited Fujita Health University Hospital for decompensated heart failure.
Cardiometabolic Health Congress
NOVEMBER 16, 2023
Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidney disease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.
Journal of Cardiothoracic Surgery
OCTOBER 15, 2024
A 41 year old female with stage 5 chronic kidney disease undergoing hemodialysis was admitted to the hospital. Chest CT scan revealed a large mass lesion of approximately 6.0 × 3.5x4.9 cm in size in the anteri.
DAIC
APRIL 6, 2024
While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24, 24, being held in Atlanta, GA.
Journal of the American Heart Association
FEBRUARY 16, 2024
Fifteen parameters were selected to assess in‐hospital mortality. ConclusionsThe PRECISE score demonstrated high predictive performance and directly translates into the expected in‐hospital mortality rate. However, a systemic predictive model estimating the mortality of refractory ischemic CS is lacking.
Circulation: Cardiovascular Quality & Outcomes
DECEMBER 6, 2023
Background:Overall outcomes and the escalation rate for home hospital admissions for heart failure (HF) are not known. Escalation of care was defined as transfer to an inpatient hospital setting (emergency department, inpatient medical unit) for at least 1 overnight stay. had chronic kidney disease, and 60.6% were White.
Journal of the American Heart Association
MARCH 27, 2025
Six multimorbidity patterns were identified, including 4 specific patterns: (1) pattern 1, cerebrovascular cluster (histories of cerebrovascular disease and hypertension); (2) pattern 2, traditional cardiovascular disease risk factors cluster (histories of hyperlipidemia, obesity, anddiabetes, and family history of cardiovascular disease and smoking); (..)
Open Heart
MARCH 23, 2023
It is risk factor for cardiovascular disease, stroke and kidney disease. Hence, this study aimed to assess blood pressure (BP) self-monitoring practice and associated factors among adult hypertensive patients on follow-up in South Wollo Zone public hospitals, Northeast Ethiopia. and then exported to SPSS V.25
Journal of the American Heart Association
JANUARY 31, 2024
The primary efficacy end point was the composite of cardiovascular death and hospitalizations for heart failure. The secondary efficacy end points were all‐cause death, cardiovascular death, hospitalizations for heart failure, kidney disease progression, and acute kidney injury.
DAIC
APRIL 9, 2024
UC Davis Medical Center is one of the first sites nationwide to have commercial access to TriClip and is the first hospital in Western United States to utilize the system since it was approved by the U.S. Left untreated, tricuspid regurgitation can lead to atrial fibrillation , heart failure , kidney disease and even death.
111 Journal of the American Heart Association
MARCH 21, 2025
Study end points include mortality, cardiovascular events (hospitalization for acute myocardial infarction or stroke) and limb events (hospitalization for critical limb ischemia or major amputation) and were identified using Veterans Affairs and nonVeterans Affairs encounters.ResultsThe mean age was 70.6 were male, and 18.5%
DAIC
JANUARY 18, 2024
Sinai hospital in New York City by Drs. The Summa Finesse Injectable has tremendous market potential and may become the standard of care when treating patients with chronic kidney disease, for whom contrast sparing is paramount.” Calf angiogram obtained using the Summa Finesse catheter with 1 ml equivalent of 60% contrast.
105 
Journal of Clinical Investigation - Cardiology
FEBRUARY 3, 2025
Ischemic acute kidney injury (AKI) is common in hospitalized patients and increases the risk for chronic kidney disease (CKD). Here, we identify a critical role for endothelial oxygen sensing prolyl hydroxylase domain (PHD) enzymes 13 in regulating postischemic kidney repair.
Frontiers in Cardiovascular Medicine
MARCH 3, 2024
Background Preeclampsia (PE) is associated with subsequent higher risk of cardiovascular and kidney disease. Serum copeptin, as a proxy for vasopressin, and urinary uromodulin, were associated with PE physiopathology and kidney functional mass respectively.
Frontiers in Cardiovascular Medicine
DECEMBER 20, 2023
Background As a sensitive diagnostic marker for myocardial infarction (MI) in people with normal renal function, elevated high sensitivity cardiac troponin T (hs-cTnT) was often found in chronic kidney disease (CKD) patients requiring dialysis.
Frontiers in Cardiovascular Medicine
APRIL 18, 2024
Binary logistic regression identified five critical determinants regarding poor renal recovery, including chronic kidney disease (CKD) history, renal hypoperfusion, circulation arrest time, intraoperative urine, and myoglobin. The assessment of the predictive model was good, with an area under the curve (AUC) of 0.73 (95% CI: 0.69–0.76),
52 
Hypertension Journal
OCTOBER 11, 2023
BACKGROUND:Despite increasing incidences of hypertension, recent trends in mortality and urgent dialysis following acute hypertension (AHT) remain undetermined.METHODS:This retrospective observational cohort study evaluated 50 316 hospitalized AHT patients from 2010 to 2019, using an administrative claims database in Japan.
40 
Journal of Cardiovascular Pharmacology
OCTOBER 9, 2024
137 patients diagnosed with AF who presented with overt GIB were evaluated during their hospitalization, at one month and one year post-discharge, and then annually. 137 patients diagnosed with AF who presented with overt GIB were evaluated during their hospitalization, at one month and one year post-discharge, and then annually.
DAIC
APRIL 7, 2024
Akshay Desai, MD “Compared to placebo, a single injection of zilebesiran resulted in clinically meaningful reductions in blood pressure at three months when added to commonly used antihypertensive treatments,” said Akshay Desai, MD, MPH , a cardiologist at Brigham and Women’s Hospital in Boston and a study coauthor. “In
111 Circulation
NOVEMBER 11, 2024
Data was obtained from the Hospital Corporation of America (HCA) enterprise-wide database from January 2020 to September 2023 using the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). Differences in baseline characteristics were analyzed between the two groups.
Journal of the American Heart Association
JANUARY 19, 2024
The CANVAS Program included participants with type 2 diabetes at elevated cardiovascular risk, whereas the CREDENCE trial included participants with type 2 diabetes and albuminuric chronic kidney disease. Canagliflozin reduced the risk of major adverse cardiovascular events (HR, 0.84 [95% CI, 0.76–0.94])
Circulation
NOVEMBER 11, 2024
Background:Heart failure (HF) is one of the leading causes of hospitalizations in the States. Results:We included 4,454,273 weighted hospitalizations due to HF for which 380,446 patients (8.5%) had a concurrent diagnosis of hyperkalemia. Circulation, Volume 150, Issue Suppl_1 , Page A4113864-A4113864, November 12, 2024.
40 
Stroke Journal
FEBRUARY 1, 2024
We aim to further characterize this risk and its in hospital consequences using a large population based sample over a 20 year study period.Methods:Using the Nationwide Inpatient Sample (2000-2019), we selected for patients who had ICH. Pregnant patients experienced lower in-hospital mortality (12.4% vs 16.2%, p<0.001).
40 
Dr. Smith's ECG Blog
SEPTEMBER 5, 2024
She presented to an outside hospital after several days of malaise and feeling unwell. A VSR is more likely to occur in patients who are older, female, hypertensive, have chronic kidney disease, and have no prior history of smoking. At the time of admission, her vital signs were normal. Heart rate was in the 80s.
European Journal of Heart Failure
JANUARY 23, 2025
ABSTRACT Aims The sodiumglucose cotransporter 2 inhibitor canagliflozin reduces the risk of heart failure (HF) hospitalization or cardiovascular death and chronic kidney disease (CKD) progression among patients with type 2 diabetes at high cardiovascular risk or with CKD.
40 
Circulation
NOVEMBER 11, 2024
The serum creatinine and serum uric acid elevated as the day of hospitalization increased, and the maximum was observed at day-7 i.e., 1.35 ± 0.54 Conclusion:The FeUa seems to be a negative predictor of CRS in patients hospitalized with ADHF. mg/ml and 11.08 ± 15.83 mg/ml, respectively.
Stroke Journal
FEBRUARY 1, 2024
Methods:We performed a retrospective cohort study using population-based data from the State Inpatient Databases and State Emergency Department Databases from New York (2006-2015), California (2003-2011), and Florida (2005-2015) to determine the association between hospital-documented migraine and retinal stroke. vs. 5.1%, SD 0.12).
40 
Stroke Journal
FEBRUARY 1, 2024
We aimed to compare in-hospital mortality and predictors in stroke patients with secondary rheumatological conditions.Methods:Using the National Inpatient Sample (NIS), we identified patients ≥18 admitted for stroke (Jan 2019 - Dec 2020), stratified into RA, SLE, scleroderma, or vasculitides groups using ICD-10-CM codes.
40 
Cardiometabolic Health Congress
NOVEMBER 8, 2023
2023, the American Heart Association (AHA) issued a presidential advisory on the urgency of this systemic disorder involving heart disease, kidney disease, diabetes and obesity. Eckel, MD , chair of the Foundations of Cardiometabolic Health Certificate Course, has held appointments such as the Charles A.
Open Heart
JULY 20, 2022
post-MDT; p<0.001), initiation of renin–angiotensin aldosterone system inhibitors in HF with reduced ejection fraction (HFrEF) with advanced chronic kidney disease (9% pre vs 71% post-MDT; p<0.001). post-MDT; p<0.001), reduction of 1586 hospital bed-days and cost savings of £634 400.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content